MiR-103a-3p aggravates renal cell carcinoma by targeting TMEM33

Jingyu Zhang; Qingbo Lu; Haigang Pang; Min Zhang; Wenhai Wei

MiR-103a-3p aggravates renal cell carcinoma by targeting TMEM33

Am J Transl Res. 2021 Nov 15;13(11):12694-12703. eCollection 2021.

Authors

Jingyu Zhang¹, Qingbo Lu², Haigang Pang³, Min Zhang⁴, Wenhai Wei⁵

Affiliations

¹ Department of Urology, The Fourth People's Hospital of Shenyang Shenyang 110031, Liaoning Province, China.
² Department of Emergency, Ningyang County First People's Hospital Tai'an 271400, Shandong Province, China.
³ Department of Urology, The 971st Hospital of Chinese People's Liberation Army Navy Qingdao 266071, Shandong Province, China.
⁴ Department of Geriatrics, Sishui County People's Hospital Ji'ning 273200, Shandong Province, China.
⁵ Department of Anesthesiology, Shouguang Maternal and Child Care Hospital Weifang 262700, Shandong Province, China.

PMID: 34956484
PMCID: PMC8661195

Abstract

Objective: We investigated the mechanism of miR-103a-3p-mediated renal cell carcinoma (RCC) progression.

Methods: The miR-103a-3p expressions were measured in clinical samples and in two RCC cell lines. MiR-103a-3p was inhibited or over-expressed in the 786-O and UO31 cell lines, respectively.

Results: We found that miR-103a-3p is closely related to the development of RCC cells. A bioinformatics analysis and a dual-luciferase reporter gene assay revealed that there is a direct interaction between TMEM33 and miR-103a-3p. Moreover, a rescue assay further confirmed that TMEM33 overexpression can attenuate miR-103a-3p-induced RCC cell development.

Conclusion: miR-103a-3p exerts a carcinogenic function in RCC by regulating TMEM33, a finding that may provide new insights into the development of prognostic markers and therapeutic targets for RCC.

Keywords: Renal cell carcinoma; TMEM33; metastasis; miR-103a-3p; proliferation.